Cardiol Therapeutics (CRDL) Net Equity Issued and Repurchased (2021 - 2026)
Cardiol Therapeutics (CRDL) posted Net Equity Issued and Repurchased of $10.8 million for Q1 2026, down 78.01% on a QoQ basis from $49.3 million in Q4 2021.
Cardiol Therapeutics (CRDL) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Cardiol Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $10.8 million for Q1 2026.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.1 million (changed N/A YoY) and the FY2021 annual result came in at $67.1 million, up 421.06% from the prior year.
- Net Equity Issued and Repurchased was $10.8 million for Q1 2026 at Cardiol Therapeutics, down from $49.3 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $10.8 million in Q1 2026 and bottomed at $10.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Cardiol Therapeutics | 134.05 Mn | 134.05 Mn | - | 10.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.83 Mn |
| Mar 31, 2026 | 10.83 Mn |
| Dec 31, 2021 | 49.25 Mn |
| Dec 31, 2021 | 49.25 Mn |